
Sanofi's 12 Blockbusters: Will Investors Trust the Promise?
French drug giant Sanofi's CEO and head of R&D defended their decision to reduce earnings forecasts for 2024 in order to invest in research studies of new medicines that they believe could generate billions of dollars in annual sales. The company's shares dropped 18% when the cuts were first announced and have yet to fully recover, but the executives are confident in the potential of their pipeline and aim to position Sanofi as the world's leading immunology company.


